insights_auto
Varför har RARE gått upp 2,85%?
Gå på djupetchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
15,17 US$
arrow_upward
+2,85%(+0,42) 1 d
2 okt., 14:41:01 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för RARE …
Öppen
14,90 US$
Högt
15,28 US$
Lågt
14,67 US$
Börsvärde
1,50 md
Genomsn. vol.
5,72 mn
Volym
1,83 mn
52v högst
39,89 US$
52v lägst
12,73 US$
EPS
−5,84 US$
Beta
0,35
Utestående aktier
98,59 mn
Antal anställda
1 tn
Öppen
14,90 US$
Högt
15,28 US$
Lågt
14,67 US$
Börsvärde
1,50 md
Genomsn. vol.
5,72 mn
Volym
1,83 mn
52v högst
39,89 US$
52v lägst
12,73 US$
EPS
−5,84 US$
Beta
0,35
Utestående aktier
98,59 mn
Antal anställda
1 tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
TipRanks
·
för 1 timme sedan
Ultragenyx Launches 10-Year Gene Therapy Monitoring Program for MPS IIIA
Simply Wall St
·
för 2 dagar sedan
Ultragenyx Stock In Focus After First Sanfilippo Type A Treatment Wins FDA Approval
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Om Ultragenyx Pharmaceutical Inc
VdEmil Kakkis
Anställda1,37 tn
Grundades2010
HuvudkontorNovato, Kalifornien, USA
Sektor-
Webbplatsultragenyx.com